Cargando…

No patient left behind: The promise of immune priming with epigenetic agents

Checkpoint inhibitors, monoclonal antibodies that inhibit PD-1 or CTLA-4, have revolutionized the treatment of multiple cancers. Despite the enthusiasm for the clinical successes of checkpoint inhibitors, and immunotherapy, in general, only a minority of patients with specific tumor types actually b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carter, Corey A., Oronsky, Bryan T., Roswarski, Joseph, Oronsky, Arnold L., Oronsky, Neil, Scicinski, Jan, Lybeck, Harry, Kim, Michelle M., Lybeck, Michelle, Reid, Tony R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665084/ https://www.ncbi.nlm.nih.gov/pubmed/29123948 http://dx.doi.org/10.1080/2162402X.2017.1315486

Ejemplares similares

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents
por: Oronsky, Bryan, et al.
Publicado: (2016)

Rewriting the Epigenetic Code for Tumor Resensitization: A Review
por: Oronsky, Bryan, et al.
Publicado: (2014)

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy
por: Oronsky, Bryan, et al.
Publicado: (2016)

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies
por: Carter, Corey A., et al.
Publicado: (2016)

The War on Cancer: A Military Perspective
por: Oronsky, Bryan, et al.
Publicado: (2015)

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance
por: Oronsky, Bryan, et al.
Publicado: (2015)

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management
por: Oronsky, Bryan, et al.
Publicado: (2017)

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
por: Carter, Corey A., et al.
Publicado: (2015)

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?
por: Carter, Corey A., et al.
Publicado: (2016)

Episensitization: Defying Time’s Arrow
por: Oronsky, Bryan T., et al.
Publicado: (2015)

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis
por: Oronsky, Bryan, et al.
Publicado: (2018)

A Review of Persistent Post-COVID Syndrome (PPCS)
por: Oronsky, Bryan, et al.
Publicado: (2021)

Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment
por: Oronsky, Bryan, et al.
Publicado: (2014)

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001
por: Oronsky, Bryan, et al.
Publicado: (2016)

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor
por: Brzezniak, Christina, et al.
Publicado: (2017)

What's New in SCLC? A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome
por: Brzezniak, Christina E., et al.
Publicado: (2017)

Cushing's Syndrome, Cortisol, and Cognitive Competency: A Case Report
por: Oronsky, Neil, et al.
Publicado: (2017)

COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making
por: Larson, Christopher, et al.
Publicado: (2020)

A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)
por: Oronsky, Bryan, et al.
Publicado: (2022)

Going viral: a review of replication-selective oncolytic adenoviruses
por: Larson, Christopher, et al.
Publicado: (2015)

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells
por: Oronsky, Bryan, et al.
Publicado: (2018)

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
por: Oronsky, Bryan, et al.
Publicado: (2020)

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

The Implications of Hyponitroxia in Cancer
por: Oronsky, Bryan, et al.
Publicado: (2014)

Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx‐001
por: Oronsky, Bryan, et al.
Publicado: (2018)

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors
por: Oronsky, Bryan, et al.
Publicado: (2016)

Dysphonia after Bevacizumab Rechallenge: A Case Report
por: Carter, Corey A., et al.
Publicado: (2015)

Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19
por: Oronsky, Bryan., et al.
Publicado: (2020)

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001
por: Carter, Corey A., et al.
Publicado: (2016)

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients
por: Reid, T., et al.
Publicado: (2014)

A Review of Newly Diagnosed Glioblastoma
por: Oronsky, Bryan, et al.
Publicado: (2021)

RRx-001, A novel dinitroazetidine radiosensitizer
por: Oronsky, Bryan, et al.
Publicado: (2016)

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis
por: Carter, Corey A., et al.
Publicado: (2016)

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry
por: Zhao, Hongjuan, et al.
Publicado: (2017)

Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable Cancer
por: Oronsky, Bryan, et al.
Publicado: (2018)

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
por: Ning, Shoucheng, et al.
Publicado: (2015)

Real Time Dynamic Imaging and Current Targeted Therapies in the War on Cancer: A New Paradigm
por: Paulmurugan, Ramasamy, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_g2bgn280vrl3tjs9peck25dcdr